Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Glucocorticoid Therapy and Cushing Syndrome Clinical Presentation

  • Author: George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London); Chief Editor: Stephen Kemp, MD, PhD  more...
 
Updated: Dec 11, 2015
 

History

All patients with Cushing syndrome who receive pharmacologic glucocorticoid treatment develop Cushingoid features if exposed to a high enough dose for long enough (usually 1 mo or more). With the exception of abnormal growth, the signs of hypercortisolism are frequently subtler in pediatric patients than in adults. In children, the most common features that are observed include an increase in body weight due in part to an increase in appetite and a decrease in linear growth. Known side effects associated with chronic hypercortisolemia from any cause are outlined below.

Table 2. Effects of Glucocorticoids During Long-Term Therapy (Open Table in a new window)

System Effects
Endocrine and metabolic Suppression of hypothalamic-pituitary-adrenal (HPA) axis (adrenal suppression)



Growth failure in children



Hyperinsulinemia/insulin resistance



Abnormal glucose tolerance test result/diabetes mellitus



GI Gastric irritation, peptic ulcer



Acute pancreatitis (rare, secondary to insulin resistance and hypertriglyceridemia)



Fatty infiltration of liver (hepatomegaly, rare)



Hemopoietic Leukocytosis



Neutrophilia - Increased recruitment from bone marrow, demargination, and decreased migration from blood vessels



Lymphopenia - Migration from blood vessels to lymphoid tissue



Eosinopenia



Monocytopenia



Immune Suppression of delayed (type IV) hypersensitivity (important with Mantoux testing for tuberculosis)



Inhibition of leukocyte and tissue macrophage migration



Inhibition of cytokine secretion/action



Suppression of the primary antigen response



Musculoskeletal Osteoporosis, spontaneous fractures



Avascular necrosis of femoral and humoral heads and other bones



Myopathy (particularly of the proximal muscles [eg, unable to comb hair or climb stairs])



Ophthalmic Posterior subcapsular cataracts (more common in children)



Elevated intraocular pressure/glaucoma



CNS (neuropsychiatric disorders) Sleep disturbances, insomnia (particularly with long-acting glucocorticoids and nocturnal dosing)



Euphoria, depression, mania, psychosis (more commonly observed in adults)



Obsessive behaviors (children with hypercortisolism are often more studious)



Pseudotumor cerebri (benign increase of intracranial pressure)



Cardiovascular[4] Hypertension[5]



Congestive heart failure in predisposed patients



Other cushingoid features Moon facies (broad cheeks with temporal muscle wasting) facial plethora



Generalized and truncal obesity (more marked in adults)



Supraclavicular fat collection



Posterior cervical fat deposition (dorsocervical hump)



Glucocorticoid-induced acne



Thin and fragile skin, violaceous striae (more common in adults)



Impotence, menstrual irregularity



Decreased thyroid-stimulating hormone and triiodothyronine



Hypokalemia (with very high cortisol levels or in the presence of potassium-wasting diuretics), metabolic alkalosis



Growth failure

The severity of disturbance in height and weight depends on the duration of treatment with pharmacologic steroids or the duration of Cushing syndrome before diagnosis. Previous measurements are helpful in determining whether growth velocity is normal or reduced. In contrast to children with hypercortisolism, children with simple exogenous obesity usually have a normal or even accelerated growth velocity and are tall.

Obesity

When evaluating a child with possible Cushing syndrome, obtain information about the duration and rate of the weight gain and any attempts to lose weight. Rigorous dieting and exercise can minimize weight gain, which may delay diagnosis.

In contrast to adults with Cushing syndrome, children may have more generalized obesity, rather than centripetal "lemon on toothpicks" obesity. The child with Cushing syndrome has a similar facies to that observed in adults, with fullness and redness of the cheeks and variable temporal muscle wasting.

The presence of dorsocervical and supraclavicular fat pads is of diagnostic help but is not pathognomonic because patients with significant obesity may also have these signs. The presence of striae and rapid weight gain are also relatively nonspecific signs. Children with simple obesity usually have a normal or accelerated growth velocity.

Premature pubarche

Prepubertal males and females with endogenous Cushing syndrome commonly have premature pubic hair development in addition to their rapid weight gain. Such development is the result of excessive adrenal androgen production that can occur in both corticotropin (ACTH)-dependent and ACTH-independent Cushing syndrome.

Pubertal delay/arrest

Information should be obtained about the time of onset of puberty and its progress. When Cushing syndrome develops during puberty, normal pubertal development does not occur and commonly arrests because glucocorticoid excess inhibits gonadotropin release and also directly inhibits sex steroid secretion from the gonads.

Males who develop Cushing syndrome at puberty commonly continue to show signs of virilization, with increased pubic and androgen-dependent hair, but they do not undergo testicular enlargement, indicating that the androgens are of adrenal origin.

Cutaneous manifestations

Children with endogenous Cushing syndrome commonly notice a generalized coarsening of body hair.

Hirsutism is common (increased hair in androgen-dependent regions of the body) and may be a presenting feature in females and prepubertal males.

Hyperandrogenemia commonly causes acne, comedones, and oily skin.

Striae may be present and are typically purple. Striae are due to the combination of rapid weight gain and impaired collagen synthesis (commonly observed on the thighs, proximal arms, abdomen, and breasts).

Poor wound healing may also be present.

Thinning of the skin and easy bruising are common symptoms in adults but are not frequently observed in children.

Monilial infections are more frequent in children with Cushing syndrome. Tinea cruris, tinea pedis, and Candida albicans infection all occur more commonly, especially if glucose intolerance is present.

Muscle weakness

Muscle weakness tends to be more evident in those patients with more severe disease. Proximal muscles are affected and muscle wasting may be observed in some cases. Children may report difficulty climbing stairs, getting out of chairs, or difficulty combing their hair. Hypokalemia can exacerbate the problems of muscle weakness.

Visual disturbance

Blurred vision may accompany hyperglycemia and lens sorbitol deposition.

Cataracts (uncommon in children) may occur with prolonged high-dose administration of synthetic glucocorticoids. Interestingly, patients with endogenous CS do not develop cataracts at an excessive rate.

Cavernous sinus invasion may infrequently occur in pituitary Cushing disease but is more common in Nelson syndrome, and it may affect the cranial nerves traversing the sinus (cranial nerves III, IV, V1, VI).

Bony symptoms

A history of focal pain over the midline raises the possibility of vertebral crush fractures. Such fractures can happen with prolonged hypercortisolemia causing severe glucocorticoid-induced osteoporosis, which significantly increases the risk of fracture.

Other bony disorders include avascular necrosis of the femoral head and slipped upper femoral epiphysis. Patients may present with a history of painful limitation of hip movement and a limp.

Renal disorders

A history of polyuria requires exclusion of diabetes, which may develop in people with preexisting insulin resistance.

Hypercalciuria and nephrolithiasis may occur with hypercortisolism and immobility (eg, juvenile rheumatoid arthritis [JRA]). Patients may present with severe colicky loin to groin pain with hematuria or a history of passing a kidney stone. This complication of Cushing syndrome is rare.

Neuropsychiatric symptoms

A history of school performance should be obtained. Children with Cushing syndrome are commonly conscientious and frequently compulsive workers at school with higher than average grades. Following cure of Cushing syndrome, children may experience a decline in school performance and an increase in anxiety symptoms.

Questions should be asked about sleep. Sleep disturbance, primarily insomnia, and depression are less frequent in children than in adults but may be present in adolescents. Obstructive sleep apnea may rarely occur in children with severe obesity.

Hematologic and immune disorders

High cortisol levels suppress innate immunity and T-cell responses, placing patients at risk of severe viral and opportunistic infections. Seek information about the severity of viral illnesses and speed of recovery from illness and, importantly, about previous tuberculosis exposure because that quiescent disease may be reactivated.

Next

Physical

Physical examination of a child treated with long-term high-dose glucocorticoids should look for treatment-associated complications; for the child suspected of having Cushing syndrome, examination should aim to identify specific features that may indicate the diagnosis. The clinical features that result in presentation and diagnosis of endogenous Cushing syndrome depend on age, sex, duration of disease, and preexisting genetic background, as well as whether other adrenocortical steroids (eg, mineralocorticoids, androgens) are present in excess. See the image below.

Physical findings in Cushing syndrome. Physical findings in Cushing syndrome.

Growth failure

Restricted growth is almost universal because linear growth is very sensitive to supraphysiologic glucocorticoid levels. In patients receiving pharmacologic glucocorticoid treatment, the primary illness for which treatment is administered may also contribute considerably to growth failure. Reduction in steroid dose or treatment of Cushing syndrome restores growth velocity to normal, although catch-up growth may be poor.

Obesity

Obesity is almost always present, unless the child has adhered to a severely restricted diet and a vigorous exercise regimen. The presence of supraclavicular fat pads and a dorsocervical hump (buffalo hump) is commonly observed with exogenous or endogenous Cushing syndrome but is not pathognomonic of cortisol excess.

Lipomastia is also commonly present and may be difficult to distinguish from true breast tissue. The latter tends to feel more firm and fibrous than nonglandular fat. If areolar development is present, this suggests increased estrogen levels, making true breast tissue more likely.

Pubertal development in females

Prepubertal girls may develop premature adrenarche.

Peripubertal girls may undergo pubertal arrest, but they may also develop hirsutism (male pattern).

Postpubertal girls develop secondary amenorrhea, and they may notice softening of their breasts. Significant hyperandrogenism may cause clitoromegaly and should be looked for in those patients with other signs of significant hyperandrogenism.

The combination of premature pubic hair and lipomastia can be confusing, producing the appearance of precocious puberty.

Pubertal development in males

Prepubertally, males with Cushing syndrome may show signs of premature development of pubic hair, axillary hair, and possible phallic enlargement, although their testes remain small, indicating that androgens are of adrenal origin.

Peripubertal males do not experience testicular enlargement.

Postpubertal males may notice softening of their testes. High glucocorticoid levels cause hypogonadism, both at the level of the pituitary and also by a direct effect on the testes.

Patients with pure hypercortisolism do not develop these symptoms because the only steroid hormones present in excess are the glucocorticoids.

Blood pressure

Children and adolescents with Cushing syndrome frequently have elevated arterial blood pressure (BP). When measuring BP, ensure that the BP cuff is the appropriate size for the arm circumference because the use of a small cuff may result in artificially high readings.

Abdominal examination

Obesity makes abdominal examination difficult. High levels of ACTH may produce a linea nigra, a pigmented line extending from the umbilicus to the pubis. Palpate carefully to look for a malignant adrenal tumor, which may be large at presentation. Hepatomegaly may occur in patients with insulin resistance who have fatty liver infiltration.

Neurologic examination

Using slit-lamp microscopy, examine patients with exogenous Cushing syndrome for evidence of subcapsular cataracts.

Musculoskeletal examination

Frank muscle proximal wasting is uncommon in children, who usually have a shorter duration of disease at diagnosis and are more active. Features on examination include difficulty climbing stairs, positive Gower sign, and difficulty combing hair (proximal upper limb weakness).

Pain and restriction of hip movement may occur as a result of slipped upper femoral epiphysis or avascular necrosis of the femoral head. If such pain is present, it requires investigation. Pain may be in the hip joint or may be referred to the anterior or medial thigh or the knee. Consider focal tenderness over a spinous process of a vertebra to be a crush fracture until proven otherwise with radiologic confirmation.

With recurrent fractures in an infant with Cushing syndrome due to bilateral adrenal hyperplasia, suspect the possibility of polyostotic fibrous dysplasia due to McCune-Albright syndrome.

Skin examination

When examining the skin, look for signs of potential causes of Cushing syndrome, including pigmentation of scars, skin creases, areolae, and genitalia (associated with high ACTH levels); lentigines (Carney complex); lipomas (multiple endocrine neoplasia type 1 [MEN1]); and irregular-shaped hyperpigmented lesions (McCune-Albright syndrome).

Cutaneous complications of Cushing syndrome include striae, balding, hirsutism (androgen-dependent hair growth), facial fullness and plethora, fungal infections in skin folds, thinning of skin, and telangiectasia (particularly in long-term use of potent topical glucocorticoids).

Signs of insulin resistance (not specific for Cushing syndrome) can include acanthosis nigricans and skin tags. Acanthosis appears as thickened coarse skin, especially in axillae and groins, as well as around the back of the neck. Skin may have an unwashed appearance, although in pale-skinned children acanthosis may appear as thickened leathery skin with minimal pigmentation. The presence of skin tags frequently increases in hyperinsulinemia. Skin tags are commonly observed around the neck, upper chest, and axillae.

Infections

High glucocorticoid levels increase the risk of bacterial and fungal infections, particularly in warm moist areas of the body, including skin creases, the genitalia, under folds of fat, and on the feet.

Viral illnesses, such as varicella, may be much more severe because of relative immunosuppression and may become generalized. Patients with Cushing syndrome or those receiving pharmacologic steroids should avoid contact with varicella, they should receive zoster immunoglobulin if they do have contact, and they should receive acyclovir if they develop the illness. Siblings in the same household should not receive attenuated live-virus vaccines because of the risk of causing infection in the child who is affected. Extremely severe Cushing syndrome, usually as a result of ectopic ACTH secretion, may be associated with potentially lethal opportunistic infections.

Observe patients with evidence of previous infection with tuberculosis or who live in areas in which tuberculosis is endemic for signs of activation of disease.

Other disorders

Diagnosis can be complicated because many of the symptoms typical of Cushing syndrome can be associated with other afflictions. Disorders that may need to be ruled out include the following:

Simple exogenous obesity

Children who gain weight rapidly may have several signs in common with Cushing syndrome, including the presence of striae, dorsocervical and supraclavicular fat pads, acanthosis nigricans, skin tags, and premature pubarche. They are also at risk of slipped upper femoral epiphysis. Unlike children with Cushing syndrome, their growth velocity is usually faster than normal, and they tend to be tall for their age. Their striae are often narrower and may not be as purple, although this is not a sensitive predictor.

Hypothyroidism and growth hormone deficiency

Patients with acquired hypothyroidism have a poor height velocity that coincides with the onset of their disease, although they do not typically have a major increase in their weight. Similarly, patients with growth hormone (GH) deficiency tend to be slightly overweight but do not gain excessive amounts of weight.

Pseudohypoparathyroidism type 1a

Patients with pseudohypoparathyroidism type 1a commonly have short stature and obesity, although they also tend to have other features that include variable intellectual impairment and foreshortening of their fourth and/or fifth metacarpals and metatarsals. Patients may present in the neonatal period or in infancy with hypocalcemia and seizures, and they may have hypothyroidism due to thyrotropin (thyroid-stimulating hormone [TSH]) resistance. This disorder is due to an inactivating mutation of the stimulating G-protein (Gsa). The spectrum of severity is dependent upon the mutation, with patients who are mildly affected presenting in later childhood. This disorder should be easier to distinguish from Cushing syndrome because a patient's growth is likely to be consistently poor, as opposed to showing a sudden decline in growth velocity and increase in weight gain.

Hypothalamic disorders

Hypothalamic dysfunction most commonly occurs secondary to surgical treatment or radiation therapy for tumors in this region, including craniopharyngioma, gliomas, and germ cell tumors. This dysfunction may also rarely be due to primary hypothalamic tumors or hypothalamic failure. Symptoms of hypothalamic dysfunction include rapid weight gain due to altered satiety signaling, alteration in the sleep-wake cycle, disorders of thirst, and variable growth failure. Patients may have evidence of GH deficiency, dysregulation of GH secretion, and central hypothyroidism.

Genetic obesity syndromes

Most of these syndromes include the combination of short stature and obesity. Hypogonadism is also a common feature. Obesity is believed to be the result of dysregulation of the hypothalamus in most cases.

  • Laurence-Moon syndrome (MIM 245800)
  • Bardet-Biedl syndrome, 6 types (chromosome arms 2q31; 3p13-p12; 11q13; 15q22.3-q23; 16q21; 20p12)
  • Smith-Magenis syndrome (MIM 182290; chromosome arm 17p11.2)
  • Alström syndrome (MIM 203800; chromosome arm 2p13)
  • Cherubism (MIM 118400; chromosome arm 4p16.3)
  • Prader-Willi syndrome (MIM 176270; chromosome arm 15q11-13

Pseudo-Cushing disease

Patients with pseudo-Cushing disease have mild-to-moderate hypercortisolism that occurs as a result of chronic overactivity of the HPA axis. This disorder is observed in patients with chronic alcoholism, depression, or chronic stress, with urinary free cortisol (UFC) levels typically 100-200 mg/1.73 m2/24 h. Children with Cushing syndrome commonly have cortisol levels in this range.

Pseudo-Cushing disease is a diagnosis of exclusion because it is extremely rare in children, so all patients with UFC levels of greater than 70 mg/1.73 m2/d require further UFC measurements; if UFC levels are elevated on several occasions, patients should be investigated for Cushing syndrome.

In older adolescents and adults in whom the diagnosis of pseudo-Cushing is suspected, a dexamethasone-suppressed corticotropin-releasing hormone (CRH) test may be used to distinguish pseudo-Cushing disease from Cushing syndrome.

Previous
Next

Causes

Cushing syndrome can be classified as ACTH-dependent and ACTH-independent. ACTH-dependent causes can be further divided according to whether ACTH secretion arises from the pituitary or from an ectopic source. ACTH-independent causes can be divided further according to whether they are due to neoplasia or hyperplasia. Table 3 summarizes the causes of Cushing syndrome.

Exogenous Cushing syndrome occurs as the result of systemic absorption of pharmacologic doses of steroids with glucocorticoid activity. Most commonly, this results from oral or parenteral administration but may also be caused by inhaled steroids, topical steroids, and, occasionally, local steroid injections.

Table 3. Genetic Causes of Cushing Syndrome (Open Table in a new window)

Cause Features Genetics
MEN1 Associated with pancreatic tumors producing gastrin, insulin, and/or ACTH that may metastasize to the liver;



multigland hyperparathyroidism, pituitary tumors, lipomas, and angiofibromas



11p13



(MIM 131100)



McCune-Albright syndrome Mosaic constitutively activating postzygotic GS alpha mutation that can lead to polyostotic fibrous dysplasia, pigmented skin lesions, gonadotropin-releasing hormone–independent precocious puberty, hyperthyroidism, renal phosphate wasting, and other endocrine and nonendocrine manifestations 20q13.2



(MIM 174800)



Beckwith-Wiedemann syndrome (Risk of adrenal malignancy) Macroglossia; visceromegaly; hyperinsulinemia; omphalocele; and risk of adrenal carcinoma, nephroblastoma, hepatoblastoma, rhabdomyosarcoma, and thoracic neuroblastoma requiring biannual sonograms 11p13



(MIM 130650)



Hemihypertrophy (Risk of adrenal malignancy) Adrenal tumors in association unilateral tissue overgrowth on ipsilateral or contralateral side



Compare upper and lower limbs and look for facial asymmetry



(MIM 235000)[6]
Li-Fraumeni syndrome (Risk of adrenal malignancy) Adrenal neoplasm



Personal or family history of multiple tumors (eg, lung, breast, nasopharynx, CNS, melanoma, pancreas, gonads, prostate)



17p13.1 -TP53 gene



22q12.1



(MIM 191170; 151623)



Carney complex Primary pigmented nodular adrenal disease (PPNAD); lentigines; myxomas of the heart, skin, and breast; melanotic schwannoma; growth hormone– and prolactin-secreting pituitary adenomas; Sertoli cell tumors of the testis; multiple small hypoechoic thyroid lesions; thyroid carcinoma 2p16 and 17q22-24



(MIM 605244; 160980)



 

Previous
 
 
Contributor Information and Disclosures
Author

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece; UNESCO Chair on Adolescent Health Care, University of Athens, Greece

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research, American College of Endocrinology

Disclosure: Nothing to disclose.

Coauthor(s)

Antony Lafferty, MB, BCh 

Antony Lafferty, MB, BCh is a member of the following medical societies: Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lynne Lipton Levitsky, MD Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor of Pediatrics, Harvard Medical School

Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research

Disclosure: Received grant/research funds from Eli Lilly for pi; Received grant/research funds from NovoNordisk for pi; Received consulting fee from NovoNordisk for consulting; Partner received consulting fee from Onyx Heart Valve for consulting.

Chief Editor

Stephen Kemp, MD, PhD Former Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Thomas A Wilson, MD Professor of Clinical Pediatrics, Chief and Program Director, Division of Pediatric Endocrinology, Department of Pediatrics, The School of Medicine at Stony Brook University Medical Center

Thomas A Wilson, MD is a member of the following medical societies: Endocrine Society, Pediatric Endocrine Society, Phi Beta Kappa

Disclosure: Nothing to disclose.

References
  1. Sharma ST, Nieman LK. Cushing's syndrome: all variants, detection, and treatment. Endocrinol Metab Clin North Am. 2011 Jun. 40(2):379-91, viii-ix. [Medline]. [Full Text].

  2. Liapi C, Chrousos GP. Glucocorticoids. Jaffe SJ, Aranda JV, eds. Therapeutic Principles in Practice. 2nd ed. Philadelphia, Pa: WB Saunders; 1992. 466-475.

  3. Lacroix A, N'Diaye N, Mircescu H, Hamet P, Tremblay J. Abnormal expression and function of hormone receptors in adrenal Cushing's syndrome. Endocr Res. 1998 Aug-Nov. 24(3-4):835-43. [Medline].

  4. Laue L, Loriaux DL, Chrousos GP. Glucocorticoid antagonists and the role of glucocorticoids at the resting and stress state. Adv Exp Med Biol. 1988. 245:225-35. [Medline].

  5. Dodt C, Wellhoner JP, Schutt M, Sayk F. [Glucocorticoids and hypertension.]. Internist (Berl). 2009 Jan. 50(1):36-41. [Medline].

  6. Hoyme HE, Seaver LH, Jones KL, Procopio F, Crooks W, Feingold M. Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet. 1998 Oct 2. 79(4):274-8. [Medline].

  7. Ragnarsson O, Glad CA, Bergthorsdottir R, Almqvist EG, Ekerstad E, Widell H, et al. Body composition and bone mineral density in women with Cushing's syndrome in remission and the association with common genetic variants influencing glucocorticoid sensitivity. Eur J Endocrinol. 2015 Jan. 172 (1):1-10. [Medline].

  8. Tritos NA, Biller BM. Advances in medical therapies for Cushing's syndrome. Discov Med. 2012 Feb. 13(69):171-9. [Medline].

  9. Rizk A, Honegger J, Milian M, Psaras T. Treatment Options in Cushing's Disease. Clin Med Insights Oncol. 2012. 6:75-84. [Medline]. [Full Text].

  10. Bansal V, El Asmar N, Selman WR, Arafah BM. Pitfalls in the diagnosis and management of Cushing's syndrome. Neurosurg Focus. 2015 Feb. 38 (2):E4. [Medline].

  11. Patalano A, Brancato V, Mantero F. Adrenocortical cancer treatment. Horm Res. 2009 Jan. 71 Suppl 1:99-104. [Medline].

  12. Keil MF, Merke DP, Gandhi R, Wiggs EA, Obunse K, Stratakis CA. Quality of life in children and adolescents one-year after cure of Cushing syndrome: A prospective study. Clin Endocrinol (Oxf). 2008 Dec 17. [Medline].

  13. Abad V, Chrousos GP, Reynolds JC, Nieman LK, Hill SC, Weinstein RS. Glucocorticoid excess during adolescence leads to a major persistent deficit in bone mass and an increase in central body fat. J Bone Miner Res. 2001 Oct. 16(10):1879-85. [Medline].

  14. Agrons GA, Lonergan GJ, Dickey GE, Perez-Monte JE. Adrenocortical neoplasms in children: radiologic-pathologic correlation. Radiographics. 1999 Jul-Aug. 19(4):989-1008. [Medline]. [Full Text].

  15. Ansell BM. Overview of the side effects of corticosteroid therapy. Clin Exp Rheumatol. 1991 Jan-Feb. 9 Suppl 6:19-20. [Medline].

  16. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003 Dec. 88(12):5593-602. [Medline].

  17. Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med. 1999 May 4. 130(9):759-71. [Medline]. [Full Text].

  18. Chrousos GP. Glucocorticoid therapy. Felig P, Frohman LA, eds. Endocrinology and Metabolism. New York, NY: McGraw-Hill, Inc; 2001. 609-632.

  19. Curtis JA, Cormode E, Laski B, Toole J, Howard N. Endocrine complications of topical and intralesional corticosteroid therapy. Arch Dis Child. 1982 Mar. 57(3):204-7. [Medline].

  20. Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. 1997 Jan 16. 336(3):172-7. [Medline].

  21. Hochberg Z, Lahav M, Shen-Orr Z, Benderli A, Barzilai D. Normal values of urinary-free cortisol in children and adolescents. Isr J Med Sci. 1983 Mar. 19(3):286-8. [Medline].

  22. Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev. 2003 Aug. 24(4):523-38. [Medline]. [Full Text].

  23. Kaye TB, Crapo L. The Cushing syndrome: an update on diagnostic tests. Ann Intern Med. 1990 Mar 15. 112(6):434-44. [Medline].

  24. Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab. 1999 Dec. 84(12):4317-23. [Medline].

  25. Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP. Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J Bone Miner Res. 2007 Jan. 22(1):110-8. [Medline].

  26. Magiakou MA, Chrousos GP. Corticosteroid Therapy, Nonendocrine Disease, and Corticosteroid Withdrawal. Bardin CW, ed. Current Therapy in Endocrinology and Metabolism. 6th ed. St. Louis, Mo: Mosby; 1997. 138-142.

  27. Magiakou MA, Mastorakos G, Chrousos GP. Cushing Syndrome: Differential Diagnosis and Treatment. Wierman ME, ed. Diseases of the Pituitary: Diagnosis and Treatment. Totowa, NJ: Humana Press; 1997. 179-202.

  28. Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. 2006 Sep. 20(3):467-82. [Medline].

  29. Merke DP, Giedd JN, Keil MF, et al. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin Endocrinol Metab. 2005 May. 90(5):2531-6. [Medline]. [Full Text].

  30. Orth DN. Cushing's syndrome. N Engl J Med. 1995 Mar 23. 332(12):791-803. [Medline].

  31. Orth DN. Differential diagnosis of Cushing's syndrome. N Engl J Med. 1991 Sep 26. 325(13):957-9. [Medline].

  32. Orth DN, Kovacs WJ. The Adrenal Cortex. Wilson JD, Foster DW, Kronenberg H, Larsen PR, eds. Williams Textbook of Endocrinology. 9th ed. Philadelphia, Pa: WB Saunders; 1998. 517-665.

  33. Papanicolaou DA, Chrousos GP. Cushing's Syndrome. Rakel RE, ed. Rakel's Current Therapy. Philadelphia, Pa: WB Saunders; 1999. 631-637.

  34. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C. Cushing's syndrome after topical application of corticosteroids. Am J Dis Child. 1982 Mar. 136(3):274-5. [Medline].

  35. Shepherd FA, Hoffert B, Evans WK, Emery G, Trachtenberg J. Ketoconazole. Use in the treatment of ectopic adrenocorticotropic hormone production and Cushing's syndrome in small-cell lung cancer. Arch Intern Med. 1985 May. 145(5):863-4. [Medline].

  36. Tsai M-J, Clark JH, Schrader WT. Mechanisms of action of Hormones that Act as Transcription-Regulatory factors. Williams Textbook of Endocrinology. Philadelphia, Pa: WB Saunders; 1998. 55-95.

  37. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA. 1993 May 5. 269(17):2232-8. [Medline].

 
Previous
Next
 
Diagnosis of Cushing syndrome.
Etiology of Cushing syndrome.
Physical findings in Cushing syndrome.
Table 1. Glucocorticoid Equivalencies [2]
Type Drug Dose Relative Glucocorticoid Potency Relative Mineralocorticoid Potency Plasma Half-Life



(mg)



Biologic Half-Life



(h)



Short-acting Cortisol 20 1.0 2 90 8-12
Hydrocortisone 25 0.8 2 80-118 8-12
Intermediate-acting Prednisone 5 4 1 60 18-36
Prednisolone 5 4 1 115-200 18-36
Triamcinolone 4 5 0 30 18-36
Methylprednisolone 4 5 0 180 18-36
Long-acting Dexamethasone 0.5 25-50 0 200 36-54
Betamethasone 0.6 25-50 0 300 36-54
Mineralocorticoid Aldosterone 0.3 0 300 15-20 8-12
Fludrocortisone 2 15 150 200 18-36
Desoxycorticosterone acetate 0 0 20 70
Table 2. Effects of Glucocorticoids During Long-Term Therapy
System Effects
Endocrine and metabolic Suppression of hypothalamic-pituitary-adrenal (HPA) axis (adrenal suppression)



Growth failure in children



Hyperinsulinemia/insulin resistance



Abnormal glucose tolerance test result/diabetes mellitus



GI Gastric irritation, peptic ulcer



Acute pancreatitis (rare, secondary to insulin resistance and hypertriglyceridemia)



Fatty infiltration of liver (hepatomegaly, rare)



Hemopoietic Leukocytosis



Neutrophilia - Increased recruitment from bone marrow, demargination, and decreased migration from blood vessels



Lymphopenia - Migration from blood vessels to lymphoid tissue



Eosinopenia



Monocytopenia



Immune Suppression of delayed (type IV) hypersensitivity (important with Mantoux testing for tuberculosis)



Inhibition of leukocyte and tissue macrophage migration



Inhibition of cytokine secretion/action



Suppression of the primary antigen response



Musculoskeletal Osteoporosis, spontaneous fractures



Avascular necrosis of femoral and humoral heads and other bones



Myopathy (particularly of the proximal muscles [eg, unable to comb hair or climb stairs])



Ophthalmic Posterior subcapsular cataracts (more common in children)



Elevated intraocular pressure/glaucoma



CNS (neuropsychiatric disorders) Sleep disturbances, insomnia (particularly with long-acting glucocorticoids and nocturnal dosing)



Euphoria, depression, mania, psychosis (more commonly observed in adults)



Obsessive behaviors (children with hypercortisolism are often more studious)



Pseudotumor cerebri (benign increase of intracranial pressure)



Cardiovascular[4] Hypertension[5]



Congestive heart failure in predisposed patients



Other cushingoid features Moon facies (broad cheeks with temporal muscle wasting) facial plethora



Generalized and truncal obesity (more marked in adults)



Supraclavicular fat collection



Posterior cervical fat deposition (dorsocervical hump)



Glucocorticoid-induced acne



Thin and fragile skin, violaceous striae (more common in adults)



Impotence, menstrual irregularity



Decreased thyroid-stimulating hormone and triiodothyronine



Hypokalemia (with very high cortisol levels or in the presence of potassium-wasting diuretics), metabolic alkalosis



Table 3. Genetic Causes of Cushing Syndrome
Cause Features Genetics
MEN1 Associated with pancreatic tumors producing gastrin, insulin, and/or ACTH that may metastasize to the liver;



multigland hyperparathyroidism, pituitary tumors, lipomas, and angiofibromas



11p13



(MIM 131100)



McCune-Albright syndrome Mosaic constitutively activating postzygotic GS alpha mutation that can lead to polyostotic fibrous dysplasia, pigmented skin lesions, gonadotropin-releasing hormone–independent precocious puberty, hyperthyroidism, renal phosphate wasting, and other endocrine and nonendocrine manifestations 20q13.2



(MIM 174800)



Beckwith-Wiedemann syndrome (Risk of adrenal malignancy) Macroglossia; visceromegaly; hyperinsulinemia; omphalocele; and risk of adrenal carcinoma, nephroblastoma, hepatoblastoma, rhabdomyosarcoma, and thoracic neuroblastoma requiring biannual sonograms 11p13



(MIM 130650)



Hemihypertrophy (Risk of adrenal malignancy) Adrenal tumors in association unilateral tissue overgrowth on ipsilateral or contralateral side



Compare upper and lower limbs and look for facial asymmetry



(MIM 235000)[6]
Li-Fraumeni syndrome (Risk of adrenal malignancy) Adrenal neoplasm



Personal or family history of multiple tumors (eg, lung, breast, nasopharynx, CNS, melanoma, pancreas, gonads, prostate)



17p13.1 -TP53 gene



22q12.1



(MIM 191170; 151623)



Carney complex Primary pigmented nodular adrenal disease (PPNAD); lentigines; myxomas of the heart, skin, and breast; melanotic schwannoma; growth hormone– and prolactin-secreting pituitary adenomas; Sertoli cell tumors of the testis; multiple small hypoechoic thyroid lesions; thyroid carcinoma 2p16 and 17q22-24



(MIM 605244; 160980)



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.